Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors and the Risk of Diabetic Ketoacidosis: an Example of Complementary Evidence for Rare Adverse Events.
American Journal of Epidemiology（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined